Clinical Trial

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
evaluate the efficacy of hyaluronidase in different doses as an adjuvant to bupivacaine in ultrasound-guided TAB block during CS
Trial Details
NCT Number NCT06839391
Lead Sponsor Benha University
Conditions Tab Block Qaulity
Enrollment 120 participants
Start Date 2025-03
Primary Completion 2026-03 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-02-21